White Paper: Better Screening for Hepatitis C Could Lower Health Costs

Researchers from OptumInsight’s life sciences group conducted a study in conjunction with scientists from a number of leading academic and medical centers to evaluate the medical benefits and cost-effectiveness of screening the “baby boomer plus” generation born from 1946 to 1970 for the hepatitis C virus (HCV).

The study comes at a time when U.S. health authorities are considering age-based or birth-cohort screening—especially for the baby boomer plus generation, the single largest demographic group perceived most at risk—and in the wake of the FDA’s approval of the first two new treatments for HCV in 20 years.

The researchers demonstrated that the additional costs of birth-cohort screening would be offset by tens of thousands of fewer cases of HCV-related liver cancer, liver transplants, and deaths—and that if the United States continues its current HCV screening practice, about one million HCV-infected residents between 40–64 years of age will remain undiagnosed.

View the full white paper to read more about lowering health costs through better screening for Hepatitis C.